Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN

Clinical Cancer Research

Volumn 9, Issue 11, 2003, Pages 4151-4158

  Bäcklund, L Magnus ^b   Nilsson, Bo R ^b   Goike, Helena M ^b   Schmidt, Esther E ^a   Liu, Lu ^a   Ichimura, Koichi ^a   Collins, V Peter ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2B; EPIDERMAL GROWTH FACTOR RECEPTOR; LOMUSTINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN CDKN2A; PROTEIN MDM2; PROTEIN P14; PROTEIN P53; PROTEIN RB1; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENETIC CODE; GENETIC POLYMORPHISM; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REGRESSION ANALYSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CHILD; FEMALE; GENES, TUMOR SUPPRESSOR; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; RETINOBLASTOMA PROTEIN; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 17144452027     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Curran, W. J., Jr., Scott, C. B., Horton, J., Nelson, J. S., Weinstein, A. S., Fischbach, A. J., Chang, C. H., Rotman, M., Asbell, S. O., Krisch, R. E., et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J. Natl. Cancer Inst. (Bethesda), 85: 704-710, 1993.
2. Barker, F. G., II, Prados, M. D., Chang, S. M., Gutin, P. H., Lamborn, K. R., Larson, D. A., Malec, M. K., McDermott, M. W., Sneed, P. K., Wara, W. M., and Wilson, C. B. Radiation response and survival time in patients with glioblastoma multiforme. J. Neurosurg., 84: 442-448, 1996.
3. Burger, P. C., and Green, S. B. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer (Phila.), 59: 1617-1625, 1987.
4. Salminen, E., Nuutinen, J. M., and Huhtala, S. Multivariate analysis of prognostic factors in 106 patients with malignant glioma. Eur. J. Cancer, 32A: 1918-1923, 1996.
5. Bleehen, N. M., and Stenning, S. P. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br. J. Cancer, 64: 769-774, 1991.
6. Walker, M. D., Strike, T. A., and Sheline, G. E. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys., 5: 1725-1731, 1979.
7. Burton, E. C., Lamborn, K. R., Forsyth, P., Scott, J., O'Campo, J., Uyehara-Lock, J., Prados, M., Berger, M., Passe, S., Uhm, J., O'Neill, B. P., Jenkins, R. B., and Aldape, K. D. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin. Cancer Res., 8: 180-187, 2002.
8. Galanis, E., Buckner, J., Kimmel, D., Jenkins, R., Alderete, B., O'Fallon, J., Wang, C. H., Scheithauer, B. W., and James, C. D. Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Int. J. Oncol., 13: 717-724, 1998.
9. James, C. D., Galanis, E., Frederick, L., Kimmel, D. W., Cunningham, J. M., Atherton-Skaff, P. J., O'Fallon, J. R., Jenkins, R. B., Buckner, J. C., Hunter, S. B., Olson, J. J., and Scheithauer, B. W. Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation. Int. J. Oncol., 15: 547-553, 1999.
10. Kraus, J. A., Glesmann, N., Beck, M., Krex, D., Klockgether, T., Schackert, G., and Schlegel, U. Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J. Neuro-Oncol., 48: 89-94, 2000.
11. Newcomb, E. W., Bhalla, S. K., Parrish, C. L., Hayes, R. L., Cohen, H., and Miller, D. C. bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status. Acta Neuropathol. (Berl), 94: 369-375, 1997.
12. Olson, J. J., Barnett, D., Yang, J., Assietti, R., Cotsonis, G., and James, C. D. Gene amplification as a prognostic factor in primary brain tumors. Clin. Cancer Res., 4: 215-222, 1998.
13. Simmons, M. L., Lamborn, K. R., Takahashi, M., Chen, P., Israel, M. A., Berger, M. S., Godfrey, T., Nigro, J., Prados, M., Chang, S., Barker, F. G., II, and Aldape, K. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res., 61: 1122-1128, 2001.
14. Smith, J. S., Tachibana, I., Passe, S. M., Huntley, B. K., Borell, T. J., Iturria, N., O'Fallon, J. R., Schaefer, P. L., Scheithauer, B. W., James, C. D., Buckner, J. C., and Jenkins, R. B. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J. Natl. Cancer Inst. (Bethesda), 93: 1246-1256, 2001.
15. Zhou, X. P., Li, Y. J., Hoang-Xuan, K., Laurent-Puig, P., Mokhtari, K., Longy, M., Sanson, M., Delattre, J. Y., Thomas, G., and Hamelin, R. Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int. J. Cancer, 84: 150-154, 1999.
16. Raffel, C., Frederick, L., O'Fallon, J. R., Atherton-Skaff, P., Perry, A., Jenkins, R. B., and James, C. D. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin. Cancer Res., 5: 4085-4090, 1999.
17. Collins, V. P. Gene amplification in human gliomas. Glia, 15: 289-296, 1995.
18. He, J., Olson, J. J., and James, C. D. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res., 55: 4833-4836, 1995.
19. Ichimura, K., Bolin, M. B., Goike, H. M., Schmidt, E. E., Moshref, A., and Collins, V. P. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res., 60: 417-424, 2000.
20. Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E. E., and Collins, V. P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res., 53: 2736-2739, 1993.
21. Schmidt, E. E., Ichimura, K., Goike, H. M., Moshref, A., Liu, L., and Collins, V. P. Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts. J. Neuropathol. Exp. Neurol., 58: 1170-1183, 1999.
22. Rasheed, B. K., McLendon, R. E., Herndon, J. E., Friedman, H. S., Friedman, A. H., Bigner, D. D., and Bigner, S. H. Alterations of the TP53 gene in human gliomas. Cancer Res., 54: 1324-1330, 1994.
23. Ueki, K., Ono, Y., Henson, J. W., Efird, J. T., von Deimling, A., and Louis, D. N. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res., 56: 150-153, 1996.
24. Buschges, R., Weber, R. G., Actor, B., Lichter, P., Collins, V. P., and Reifenberger, G. Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. Brain Pathol., 9: 435-442; discussion 432-433, 1999.
25. Costello, J. F., Plass, C., Arap, W., Chapman, V. M., Held, W. A., Berger, M. S., Su Huang, H. J., and Cavenee, W. K. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res., 57: 1250-1254, 1997.
26. Riemenschneider, M. J., Buschges, R., Wolter, M., Reifenberger, J., Bostrom, J., Kraus, J. A., Schlegel, U., and Reifenberger, G. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res., 59: 6091-6096, 1999.
27. Smith, J. S., Wang, X. Y., Qian, J., Hosek, S. M., Scheithauer, B. W., Jenkins, R. B., and James, C. D. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J. Neuropathol. Exp. Neurol., 59: 495-503, 2000.
28. Westermark, B., Heldin, C. H., and Nister, M. Platelet-derived growth factor in human glioma. Glia, 15: 257-263, 1995.
29. Sherr, C. J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res., 60: 3689-3695, 2000.
30. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
31. Ichimura, K., Schmidt, E. E., Goike, H. M., and Collins, V. P. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene, 13: 1065-1072, 1996.
32. Ekstrand, A. J., James, C. D., Cavenee, W. K., Seliger, B., Pettersson, R. F., and Collins, V. P. Genes for epidermal growth factor receptor, transforming growth factor α, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res., 51: 2164-2172, 1991.
33. Liu, L., Ichimura, K., Pettersson, E. H., Goike, H. M., and Collins, V. P. The complexity of the 7p12 amplicon in human astrocytic gliomas: detailed mapping of 246 tumors. J. Neuropathol. Exp. Neurol., 59: 1087-1093, 2000.
34. Sauter, G., Maeda, T., Waldman, F. M., Davis, R. L., and Feuerstein, B. G. Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am. J. Pathol., 148: 1047-1053, 1996.
35. Kleihues, P., and Cavanee, W. K. WHO Classification of Tumours, Pathology and Genetics of the Nervous system: IARC Press, 2000.
36. Liu, L., Ichimura, K., Pettersson, E. H., and Collins, V. P. Chromosome 7 Rearrangements in Glioblastomas; Loci Adjacent to EGFR Are Independently Amplified. J. Neuropathol. Exp. Neurol., 57: 1138-1145, 1998.
37. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
38. Gehan, E. A. A generalized two-sample Wilcoxon test for doubly censored data. Biometrika, 52: 650-653, 1965.
39. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., and Smith, P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer, 35: 1-39, 1977.
40. Morgenbesser, S. D., Williams, B. O., Jacks, T., and DePinho, R. A. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature (Lond.), 371: 72-74, 1994.
41. Debbas, M., and White, E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev., 7: 546-554, 1993.
42. Wu, X., and Levine, A. J. p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA, 91: 3602-3606, 1994.
43. Kurose, K., Gilley, K., Matsumoto, S., Watson, P. H., Zhou, X. P., and Eng, C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat. Genet., 32: 355-357, 2002.
44. Kato, H., Kato, S., Kumabe, T., Sonoda, Y., Yoshimoto, T., Han, S. Y., Suzuki, T., Shibata, H., Kanamaru, R., and Ishioka, C. Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin. Cancer Res., 6: 3937-3943, 2000.
45. Bauman, G. S., Ino, Y., Ueki, K., Zlatescu, M. C., Fisher, B. J., Macdonald, D. R., Stitt, L., Louis, D. N., and Cairncross, J. G. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int. J. Radiat. Oncol. Biol. Phys., 48: 825-830, 2000.
46. Cairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., Ramsay, D. A., and Louis, D. N. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. (Bethesda), 90: 1473-1479, 1998.
47. Watanabe, K., Tachibana, O., Sata, K., Yonekawa, Y., Kleihues, P., and Ohgaki, H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol., 6: 217-223; discussion 223-224, 1996.
48. Reifenberger, J., Ring, G. U., Gies, U., Cobbers, L., Oberstrass, J., An, H. X., Niederacher, D., Wechsler, W., and Reifenberger, G. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J. Neuropathol. Exp. Neurol., 55: 822-831, 1996.
49. Tohma, Y., Gratas, C., Biernat, W., Peraud, A., Fukuda, M., Yonekawa, Y., Kleihues, P., and Ohgaki, H. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J. Neuropathol. Exp. Neurol., 57: 684-689, 1998.
50. Biernat, W., Kleihues, P., Yonekawa, Y., and Ohgaki, H. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J. Neuropathol. Exp. Neurol., 56: 180-185, 1997.
51. Biernat, W., Tohma, Y., Yonekawa, Y., Kleihues, P., and Ohgaki, H. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol. (Berl), 94: 303-309, 1997.
52. Nakamura, M., Watanabe, T., Klangby, U., Asker, C., Wiman, K., Yonekawa, Y., Kleihues, P., and Ohgaki, H. p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol., 11: 159-168, 2001.